Applications and solutions
Using clinical and molecular data for better decisions
Molecular Health software applications and services allow you to leverage our comprehensive data of clinico-molecular drugs, diseases, and phenotypes for evidence-based drug development, diagnosis, and medication.
Our applications are designed to predict drug therapy outcomes, clinical trial designs, drug-induced adverse effects, and drug-drug interactions – out-of-the box. Molecular data has finally become meaningful at the clinical level.
Gaining insights has never been easier
Dataome has become one of the largest globally available resources of clinico-molecular data and knowledge. From millions of patient lives to hundreds of billions of molecular data points, it provides a single point of access to the world’s biomedical knowledge through our decision support applications.
Molecular Health Guide (MH Guide) identifies safe and effective medication for cancer patients by analyzing the cancer’s molecular profile. It matches detected tumor mutations to the world’s knowledge in the field of oncology and helps medical experts to create a patient-specific clinical report with treatment recommendations.
Molecular Health Guide Mendel (MH Mendel) supports human geneticists in diagnosing hereditary diseases and creating diagnostic reports for individuals. The germline data analysis follows official genetic guidelines and uses the latest, world known ACMG variant classification criteria.
Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants for hereditary breast and ovarian cancer. It creates individual reports based on genetic variants in BRCA1/BRCA2 and other associated genes following official genetic guidelines.
Molecular Health Predict (MH Predict) is an application to predict clinical trials probabilities of success. It enables the improvement of clinical trial success and reduces clinical trial failure while optimizing resource allocation for the biopharma industry and investors and enhancing the overall efficiency of drug development.